Treatment of hepatitis C in children with direct-acting antiviral drugs

Krestine Rosager Hansen; Jesper Kjærgaard; Helene Kvistgaard; Dorthe Grosen; Mette Holm; Jan Gerstoft; Sannie Nordly; Thora Wesenberg Helt; Vibeke Brix Christensen

doi:10.61409/V08230522

Treatment of hepatitis C in children with direct-acting antiviral drugs

Translated title of the contribution: Not Available

Krestine Rosager Hansen, Jesper Kjærgaard, Helene Kvistgaard, Dorthe Grosen, Mette Holm, Jan Gerstoft, Sannie Nordly, Thora Wesenberg Helt, Vibeke Brix Christensen

Abstract

The primary purpose of treating chronic hepatitis C (HCV) is to prevent the development of liver fibrosis, cirrhosis, and cancer. In the last decade, direct-acting antiviral medicine (DAA) has been approved to treat children with HCV. This treatment has a higher efficacy, shorter duration, and milder side effects than the previously approved treatment. In this review, it is recommended to track down children who might be infected with HCV to enhance early treatment to prevent transmission of the virus and the possible complications.

Translated title of the contribution	Not Available
Original language	Danish
Article number	V08230522
Journal	Ugeskrift for Laeger
Volume	186
Issue number	1
ISSN	0041-5782
DOIs	https://doi.org/10.61409/V08230522
Publication status	Published - 1 Jan 2024

Access to Document

10.61409/V08230522

Cite this

@article{bc0e01f82c2f48ac8538cfc79f75f43b,

title = "Treatment of hepatitis C in children with direct-acting antiviral drugs",

abstract = "The primary purpose of treating chronic hepatitis C (HCV) is to prevent the development of liver fibrosis, cirrhosis, and cancer. In the last decade, direct-acting antiviral medicine (DAA) has been approved to treat children with HCV. This treatment has a higher efficacy, shorter duration, and milder side effects than the previously approved treatment. In this review, it is recommended to track down children who might be infected with HCV to enhance early treatment to prevent transmission of the virus and the possible complications.",

keywords = "Antiviral Agents/adverse effects, Child, Hepacivirus, Hepatitis C, Hepatitis C, Chronic/drug therapy, Humans, Liver Cirrhosis/complications",

author = "Hansen, {Krestine Rosager} and Jesper Kj{\ae}rgaard and Helene Kvistgaard and Dorthe Grosen and Mette Holm and Jan Gerstoft and Sannie Nordly and Helt, {Thora Wesenberg} and Christensen, {Vibeke Brix}",

note = "Published under Open Access CC-BY-NC-BD 4.0. https://creativecommons.org/licenses/by-nc-nd/4.0/.",

year = "2024",

month = jan,

day = "1",

doi = "10.61409/V08230522",

language = "Dansk",

volume = "186",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "1",

}

TY - JOUR

T1 - Treatment of hepatitis C in children with direct-acting antiviral drugs

AU - Hansen, Krestine Rosager

AU - Kjærgaard, Jesper

AU - Kvistgaard, Helene

AU - Grosen, Dorthe

AU - Holm, Mette

AU - Gerstoft, Jan

AU - Nordly, Sannie

AU - Helt, Thora Wesenberg

AU - Christensen, Vibeke Brix

N1 - Published under Open Access CC-BY-NC-BD 4.0. https://creativecommons.org/licenses/by-nc-nd/4.0/.

PY - 2024/1/1

Y1 - 2024/1/1

N2 - The primary purpose of treating chronic hepatitis C (HCV) is to prevent the development of liver fibrosis, cirrhosis, and cancer. In the last decade, direct-acting antiviral medicine (DAA) has been approved to treat children with HCV. This treatment has a higher efficacy, shorter duration, and milder side effects than the previously approved treatment. In this review, it is recommended to track down children who might be infected with HCV to enhance early treatment to prevent transmission of the virus and the possible complications.

AB - The primary purpose of treating chronic hepatitis C (HCV) is to prevent the development of liver fibrosis, cirrhosis, and cancer. In the last decade, direct-acting antiviral medicine (DAA) has been approved to treat children with HCV. This treatment has a higher efficacy, shorter duration, and milder side effects than the previously approved treatment. In this review, it is recommended to track down children who might be infected with HCV to enhance early treatment to prevent transmission of the virus and the possible complications.

KW - Antiviral Agents/adverse effects

KW - Child

KW - Hepacivirus

KW - Hepatitis C

KW - Hepatitis C, Chronic/drug therapy

KW - Humans

KW - Liver Cirrhosis/complications

UR - http://www.scopus.com/inward/record.url?scp=85182954862&partnerID=8YFLogxK

U2 - 10.61409/V08230522

DO - 10.61409/V08230522

M3 - Review

C2 - 38235776

SN - 0041-5782

VL - 186

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

IS - 1

M1 - V08230522

ER -

Treatment of hepatitis C in children with direct-acting antiviral drugs

Abstract

Access to Document

Other files and links

Fingerprint

Cite this